Double versus single autotransplantation in multiple myeloma; a single center experience of 100 patients

Haematologica

Volumn 90, Issue 4, 2005, Pages 562-563

  Putkonen, Mervi ^a   Rauhala, Auvo ^b   Itälä, Maija ^a   Kauppila, Marjut ^a   Pelliniemi, Tarja Terttu ^a   Remes, Kart ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b VAASA CENTRAL HOSPITAL   (Finland)

Author keywords

Autologous stem cell transplantation; High dose therapy; Multiple myeloma

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; MELPHALAN; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CYTOREDUCTIVE SURGERY; DRUG MEGADOSE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; HUMANS; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 17844403512     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
2. Harousseau JL, Attal M. High-dose therapy in multiple myeloma. The Hematology J 2003;4:163-70.
3. Blade J, Samson D, Reece D, Apperley J, Björkstrand B, Garthon G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.
4. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:66-75.
5. Lemoli RM, Martinelli G, Zamagni E, Motta M, Rizzi S, Terragna C, et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood 2000;95:2234-9.
6. Weaver CH, Zhen B, Schwartzberg LS, Leff R, Magee M, Geier L, et al. Phase I-III evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. Bone Marrow Transplant 1998;22:245-51.
7. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502.
8. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM 95-02 randomised trial. Blood 2002;99:731-5.
9. Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995;85:3077-85.
10. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger A, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: upfront or rescue treatment? Results of multicenter sequential randomized clinical trial. Blood 1998;92:3131-6.